• Home

  • Partners

  • Work Packages

  • News and Events

  • Intranet

  • Contact Us

  • Glossary

  • More

    SUrrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools

    Address 1

    Social Links

    facebook

    twitter

    google +

    • w-facebook
    • Twitter Clean
    • w-googleplus

    We will happily help you address any related inquires. Please fill in the below form and submit your inquiry.

    FAQ page

    Jacqueline Postma, Ph.D.
    Grant manager LUDC
    Project manager IMI-SUMMIT

    Lund University Diabetes Centre
    CRC, Malmö University Hospital
    Jan Waldenströms gata 35
    SE-205 02 Malmö, Sweden
    Tel: +46 (0)40 391236
    Fax: +46 (0)40 391222
    mailto: jacqueline.postma@med.lu.se

    Dr. Markus Albertini

    Project Manager IMI-SUMMIT

    ​

    Boehringer Ingelheim Pharma GmbH & Co. KG
    Div. Research Germany
    Tel.: +49 (7351) 54-97371
    Fax: +49 (7351) 83-97371
    mailto: summit@boehringer-ingelheim.com

    

    Address 2

    Contact Us

    Navigation

    • Objectives

    • Achievements

    • Newsletter

    • Funding Partners

    • Participants

    • Publications

    • Contact

    © 2014 by IMI-SUMMIT. All rights reserved.

    Website design: Klodiana Jani

    MISSION

    T​o DISCOVER, DEVELOP and QUALIFY potential MARKERS that empower:

    ​

    • the identification of patients at high risk of diabetes complications

    • the monitoring of the complications' progression and patients‘ response to therapy 

    ​

    To use the discovered markers as SURROGATE ENDPOINTS in clinical trials.

    

    Thereby, SHORTEN the long lasting CLINICAL TRIALS to bring about EARLIER availability of NEW THERAPY to diabetic patients.

    Related Sites